Metabolic syndrome (MetS) is a group of metabolic abnormalities associated with obesity, insulin resistance, and diabetes. Its prevalence is recognized as related to increased hazard of metabolic and cardiovascular diseases. It is often associated with conditions such as atherosclerosis and arterial hypertension. While the cause-effect relationships remain to be fully elucidated, MetS is often related to occurrence and development of benign prostatic hyperplasia (BPH) and other lower urinary tract dysfunction (LUTD), including overactive bladder (OAB), underactive bladder, and incontinence. Previous studies found that about 20-50% of men with LUTS suggestive of BPH had MetS. Meanwhile, emerging evidence supports that diabetes is also associated with impaired function of the bladder. Data from experimental models of acquired diabetes also show the relationship with LUTD, especially BPH and OAB. However, the clear pathologic pathway is still not found yet. Researchers around the world suggested that insulin resistance, sex hormone abnormal and inflammatory factors disorder played important roles in the potential pathophysiological processes. Furthermore, several modifiable behaviors involved in MetS determinism, such as inadequate diet, lack of physical exercise, and smoking and substance abuse are emerging as main contributors to the development of BPH and OAB. The established treatments of BPH and OAB lack the consideration of targeting pathophysiology changes in MetS. In clinical practices, the urologists need to pay more attention to MetS-associated LUTD.
Sub-themes for this research topic may include, but are not limited to:
- Association and cause-effect evidence between MetS and related conditions on the one and BPH, OAB and other LUTD on the other hand
- Impact of MetS on the detection and treatment of BPH, OAB and other LUTD
Papers based on experimental studies and on clinical data will be equally welcome.
Metabolic syndrome (MetS) is a group of metabolic abnormalities associated with obesity, insulin resistance, and diabetes. Its prevalence is recognized as related to increased hazard of metabolic and cardiovascular diseases. It is often associated with conditions such as atherosclerosis and arterial hypertension. While the cause-effect relationships remain to be fully elucidated, MetS is often related to occurrence and development of benign prostatic hyperplasia (BPH) and other lower urinary tract dysfunction (LUTD), including overactive bladder (OAB), underactive bladder, and incontinence. Previous studies found that about 20-50% of men with LUTS suggestive of BPH had MetS. Meanwhile, emerging evidence supports that diabetes is also associated with impaired function of the bladder. Data from experimental models of acquired diabetes also show the relationship with LUTD, especially BPH and OAB. However, the clear pathologic pathway is still not found yet. Researchers around the world suggested that insulin resistance, sex hormone abnormal and inflammatory factors disorder played important roles in the potential pathophysiological processes. Furthermore, several modifiable behaviors involved in MetS determinism, such as inadequate diet, lack of physical exercise, and smoking and substance abuse are emerging as main contributors to the development of BPH and OAB. The established treatments of BPH and OAB lack the consideration of targeting pathophysiology changes in MetS. In clinical practices, the urologists need to pay more attention to MetS-associated LUTD.
Sub-themes for this research topic may include, but are not limited to:
- Association and cause-effect evidence between MetS and related conditions on the one and BPH, OAB and other LUTD on the other hand
- Impact of MetS on the detection and treatment of BPH, OAB and other LUTD
Papers based on experimental studies and on clinical data will be equally welcome.